Repair of segmental bone defects in rabbit tibia promoted by a complex of β-tricalcium phosphate and hepatocyte growth factor by Goshima Kenichi et al.
Repair of segmental bone defects in rabbit
tibia promoted by a complex of β-tricalcium
phosphate and hepatocyte growth factor
著者 Goshima Kenichi, Nakase Junsuke, Xu Qing,
Matsumoto Kunio, Tsuchiya Hiroyuki
journal or
publication title








Repair of segmental bone defects in rabbit tibia promoted
by a complex of b-tricalcium phosphate and hepatocyte
growth factor
Kenichi Goshima • Junsuke Nakase •
Qing Xu • Kunio Matsumoto • Hiroyuki Tsuchiya
Received: 23 July 2011 / Accepted: 1 June 2012 / Published online: 5 July 2012
 The Japanese Orthopaedic Association 2012
Abstract
Background Segmental bone defect repair remains a
clinical and scientific challenge with increasing interest
focused on bone tissue engineering. Clinical studies are
ongoing to address application of hepatocyte growth factor
(HGF) for treatment of some diseases; however, the use of
HGF in bone tissue engineering has not been addressed.
This study was performed to evaluate the effect of HGF in
a complex of b-tricalcium phosphate (b-TCP) and collagen
in repairing segmental bone defects.
Methods Segmental bone defects 5 mm long were created
in the middle of the tibial shafts of rabbits. The defect was
stabilized with external fixators and implanted with a com-
plex of b-TCP granules and collagen, with or without 100 lg
recombinant human HGF. Biweekly, bone regeneration and
b-TCP resorption were assessed radiographically and
histologically. At 4 and 8 weeks, bone regeneration was
evaluated by use of micro-computed tomography and
mechanical tests.
Results Compared with the bone tissue treated with
b-TCP and collagen, mineralization, angiogenesis, new
bone formation, and absorption of b-TCP were promoted
4 weeks postoperatively by treatment with HGF in the
b-TCP and collagen group. These changes were associated
with promoting biomechanical regeneration. By 8 weeks,
the formation of bone marrow in newly generated bone and
absorption of the b-TCP granules were completed in a
shorter period by combining HGF with b-TCP and colla-
gen, compared with tissues without HGF.
Conclusions The combined application of HGF in a
b-TCP and collagen matrix promoted histological bone
healing and augmented mechanical strength of the healing
bone, particularly in the early stages. The combined use of
HGF and b-TCP for treatment of bone defects made a
substantial difference.
Introduction
Segmental bone defects can result from high-energy
trauma, resection of bone tumors, or treatment of non-
union. Such bone defects have been clinically treated by
implantation of bioceramics or autogenous and allogenous
bone grafts. Although autografting is a popular procedure
for reconstructive surgery, the limited sources of bone
grafts, persistent pain, nerve damage, and cosmetic char-
acteristics at the donor site are disadvantages [1]. In con-
trast, there are no donor site problems for allografting, but
allografting has some clinical risks, for example disease
transmission and immunological reactions [2].
Bone tissue engineering has attracted much attention as
an approach to improve these problems. This new thera-
peutic technology induces bone regeneration by use of a
variety of growth factors, osteogenic cells, biocompatible
scaffolds, or a combination of these approaches [2, 3]. It is
highly likely that a combination of osteoinductive growth
factors and scaffolds provides an appropriate osteoinduc-
tive environment for osteogenic cells. Promoting bone
formation by applying polypeptide growth factors has been
reported, including bone morphogenetic protein (BMP) [4],
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fibroblast growth factor-2 (FGF-2) [5], platelet-derived
growth factor (PDGF) [6], and vascular endothelial cell
growth factor (VEGF) [7].
Among growth factors, hepatocyte growth factor (HGF),
originally identified and cloned as a growth-promoting
factor of mature hepatocytes [8], has biological activity
including promotion of cell proliferation and migration,
prevention of cell death, and induction of morphogenesis.
On the basis of this biological activity, HGF and its
receptor Met are involved in the development, repair, and
protection of tissues [9]. Administration of HGF or
expression of the HGF gene promotes tissue regeneration
and improves the pathology of a variety of disease models
of different tissues [9, 10]. A recent study demonstrated
that administration of recombinant HGF enhances tendon
healing in the bone tunnel and leads to improved biome-
chanical fixation within a shorter period postoperatively
[11]. In a bone fracture model, local expression of the HGF
gene promotes healing of bone fractures [12], and admin-
istration of HGF induces expression of the BMP receptor
[13]. These results suggest a potential application of HGF
as material-based regenerative medicine to facilitate repair
of bones and ligaments in combination with orthopedic
surgery.
Because scaffolding materials basically function as a
substrate for attachment and proliferation of osteogenic
cells during bone regeneration, three-dimensional biode-
gradable materials with a porous structure, for example
glycolide–lactide copolymer nonwoven fabrics, collagen
sponges, and calcium phosphate ceramics, have been used
[14]. b-Tricalcium phosphate (b-TCP) is a calcium phos-
phate ceramic used as an alternative bone substitute for
autografts during bone grafting. It has excellent osteocon-
duction and resorbability when filling bone defects [15].
b-TCP is also a potential carrier for local delivery of
polypeptide growth factors, including BMP-2 [16], FGF-2
[17], and PDGF [6], to promote bone healing. However, the
effects of a complex of b-TCP and HGF on bone healing
have yet to be addressed.
The objective of this study was to evaluate the effect of
a complex of b-TCP and collagen combined with HGF on
bone regeneration for segmental bone defects in a rabbit
model. This is the first study to address the therapeutic
effects of the b-TCP and HGF complex on bone healing.
Materials and methods
Materials
b-TCP was provided by Olympus Biomaterials (Tokyo,
Japan). Fine b-TCP powder was synthesized by wet milling
(a mechanochemical method). CaHPO4H2O and CaCO3 at
a molar ratio of 2:1 were mixed into a slurry with pure
water and particles of zirconium in a pot mill for 24 h,
dried at 80 C, and calcium-deficient hydroxyapatite was
obtained. This crystal was converted to b-TCP by calci-
nation at 750 C for 1 h. A porous b-TCP block was
obtained after sintering the b-TCP powder at 1050 C for
1 h. The porosity of the block was 75 % with a mean
macropore size of 200 lm. In this study, the b-TCP block
was crushed in a ceramic bowl into granules ranging in
diameter from 300 to 500 lm.
Atelocollagen, a highly purified type 1 collagen derived
from calf dermis, was obtained from Koken (Tokyo,
Japan). This telopeptide was digested with pepsin to reduce
antigenicity. Recombinant human HGF (the five amino
acid-deleted type) was obtained from Kringle Pharma
(Osaka, Japan). To prepare implants, 0.2 g -TCP granules,
0.25 ml 1 % collagen solution, and 100 lg HGF were
aseptically mixed in a dish immediately before surgery.
Animals and surgical procedure
Sixty female Japanese white rabbits, weighing between 2.5
and 3.0 kg, were used for this experiment. The animal
experiments were conducted in strict accordance with the
regulations of the Institutional Animal Care and Use
Committee of Kanazawa University, Japan. The rabbits
were anesthetized by subcutaneous injection of ketamine
hydrochloride (35 mg/kg body weight; Sankyo Pharma-
ceutical, Tokyo, Japan) and xylazine (5 mg/kg body
weight; Bayer, Tokyo, Japan), and intravenous injection of
pentobarbital sodium (40–50 mg/kg body weight; Abbott
Laboratories, Chicago, IL, USA). A longitudinal skin
incision was made on the anteromedial aspect of the right
tibia, and the periosteum was carefully stripped of sur-
rounding soft tissue and fascia. Four half pins 2 mm in
diameter (Stryker, Geneva, Switzerland) were inserted into
the medial aspect of the tibia, perpendicular to its axis, and
a unilateral external fixator of our design was applied. A
segmental bone defect 5 mm long was created in the
middle of the tibial shaft, by use of a bone saw. Muscle
attachment was repaired and the skin was closed in layers.
The animals were divided into three experimental groups
as follows. In group A (n = 20), the bone defect was filled
with a complex of b-TCP granules, collagen, and HGF
(100 lg). The volume of the complex was slightly larger
than that of the original bone defect. In group B (n = 20),
the defect was filled with a mixture of b-TCP and collagen.
In group C (n = 20), the bone defect was left empty
(Fig. 1). Six animals from each group were euthanized with
an intravenous dose of sodium pentobarbital 4 and 8 weeks
after surgery. After removing the external fixator and soft
tissue surrounding the tibia, micro-computed tomography
(CT) and biomechanical analysis was performed.
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Radiological and micro-CT analysis
After 2, 4, 6, and 8 weeks each rabbit was examined by
X-ray, under anesthesia, to evaluate new bone formation
and resorption of the b-TCP granules in the bone defect.
All animals had an anteroposterior and a mediolateral
X-ray of their operated tibia.
For detailed evaluation of the healing process, six rab-
bits in each group were examined by use of micro-CT
(SMX-100CT-SV; Shimadzu, Kyoto, Japan).
Biomechanical analysis
To evaluate 4 and 8-week bone regeneration, biomechan-
ical testing of six tibias in both groups A and B was
conducted. For this analysis, a three-point bending test was
performed using a universal testing machine (Model 4482;
Instron, Norwood, MA, USA). The maximum load (N) was
interpreted and calculated from the load–deflection curve,
which was displayed continuously on the computerized
monitor. Mechanical data ratios of the mechanical data
from the segmental bone defect tibia to the intact tibia
(percentage failure load) were calculated.
Histological analysis
Two rabbits in each group were euthanized 2, 4, 6, and
8 weeks after surgery, and the histology of the osteotomy
gap was studied. The specimens were rapidly fixed in 10 %
formalin, and conventional paraffin-embedded sections
were prepared. The specimens were sectioned at 5-lm
thickness parallel to the bone axis and stained with
hematoxylin and eosin.
Semi-quantitative evaluation of -TCP area
and new bone formation
New bone formation and the b-TCP remaining in the defect
were quantified by color-based thresholding and use of
image-analysis software (WinRoof; Mitani, Tokyo, Japan).
We colored the areas of new bone formation in pink and
those with b-TCP in blue. A square of side 2 mm in the
bone defect was defined as the total area, and area rates of
new bone formation and b-TCP were calculated relative to
this total area (Fig. 2).
Statistical analysis
All data are expressed as the mean ± SD. Statistical
analysis was performed by use of Student’s t test. Values of
p \ 0.05 were considered statistically significant.
Fig. 1 Macroscopic appearance of segmental defects. A 5-mm bone
defect was created in the middle of the tibia and stabilized with a
unilateral external fixator. The defect was implanted with a complex
of b-tricalcium phosphate (b-TCP) granules and collagen, either with
100 lg hepatocyte growth factor (HGF) (group A) or without HGF
(group B). The bone defect was left empty in the control (group C)
Fig. 2 Representative image
for semi-quantitative evaluation
of the b-tricalcium phosphate
(b-TCP) and new bone
formation areas. In tissue
sections subjected to H&E
staining, a square of side of
2 mm was defined as the total
area, and the areas of new bone
formation and of b-TCP were
calculated and expressed as a
percentage of this total area
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Results
Changes in radiological, macroscopic,
and micro-CT findings
First, the defect regions were analyzed by radiography to
evaluate healing (Fig. 3a, b). Twenty rabbits were used in
each experimental group; eight rabbits in group C were
excluded from subsequent experiments because of break-
age at the defect site owing to delayed union. The other 12
rabbits in group C were used for radiological examination
only.
In the untreated control (group C), substantial detectable
changes were not seen within 4 weeks on both the antero-
posterior (Fig. 3a) and mediolateral (Fig. 3b) radiographic
images. Marginal changes were observed at 6 weeks on the
mediolateral image and only a small amount of bone for-
mation was observed at the two ends at 8 weeks. Clearly, no
solid union was achieved in group C by 8 weeks postop-
eratively. In contrast, a clear increase in callus density and
volume was observed in group A (b-TCP, collagen, and
HGF) compared with group B (b-TCP and collagen) at 2
and 4 weeks. Anteroposterior and mediolateral radio-
graphic images indicated that synostosis was almost com-
plete 8 postoperatively in groups A and B. b-TCP granules
were clearly visible with most remaining within the defect
in groups A and B at 2 weeks. In group A, the margins of
the b-TCP granules became unclear 4 weeks postopera-
tively, indicating their absorption. Thereafter, the b-TCP
granules became time-dependently coarser, and most of the
b-TCP granules disappeared and were replaced by bone at
8 weeks. However, in group B, absorption of b-TCP gran-
ules was delayed compared to that in group A with most of
the b-TCP granules remaining at the end of 8 weeks in
group B.
The macroscopic appearance of the segmental bone
defect lesions indicated that healing of the segmental defect
was almost complete in group A, whereas bone healing
seemed to be achieved but residual b-TCP granules
remained in group B (Fig. 4).
Consistent with the changes detected by radiographic
and macroscopic observation, the micro-CT analysis indi-
cated that a solid union had formed in groups A and B at
8 weeks. At 4 weeks, b-TCP granules in group A were
coarser than those of group B. At 8 weeks, most of the
b-TCP granules had disappeared and were replaced by
bone in group A, whereas most of the b-TCP granules
remained in group B (Fig. 5). Taken together, these results
indicate that regeneration of segmental bone defect is
promoted by combinations of b-TCP and collagen (group
B) and b-TCP granules, collagen, and HGF (group A),
whereas overall regeneration, including absorption of
b-TCP granules, seemed to be best promoted by the
b-TCP, collagen, and HGF matrix.
Fig. 3 Change in the healing processes of segmental bone defects as
analyzed by anteroposterior (a) and mediolateral (b) radiographic
images. Group A were treated with a mixture of b-tricalcium
phosphate (b-TCP), collagen, and hepatocyte growth factor (HGF)
(n = 20); group B were treated with b-TCP and collagen (n = 20);
group C were untreated (n = 12). Each image is representative of
each group. Eight rabbits in group C were excluded from the analysis
because of impaired union and breakage at the defect site
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Biomechanical analysis
The legs were subjected to biomechanical examination to
determine whether facilitated regeneration of the segmental
bone defects by application of additional HGF was asso-
ciated with functional regeneration (Fig. 6). Four weeks
postoperatively, the mean ratio of failure loads in group A
was significantly greater (p = 0.002) than that of group B
(50.9 ± 12.5 vs. 29.1 ± 8.0 %, respectively). Although no
significant differences were observed, the mean ratio of
failure loads in group A tended to be slightly greater than
that in group B at 8 weeks (83.3 ± 10.4 % in group A vs.
72.7 ± 15.2 % in group B; p = 0.09).
Histological changes
Two weeks postoperatively, fibroblast-like cells charac-
teristic of granulation tissue, newly formed blood vessels,
and monocytes and/or inflammatory cells infiltrated into
the b-TCP micropores, and a small amount of immature
bone formation was observed around the b-TCP in group
A. In group B, fibroblast-like cells appeared around the
b-TCP, but angiogenesis was less than that in group A,
and immature bone formation was not seen (Fig. 7a).
Four weeks postoperatively, granulation tissue in the
b-TCP micropores underwent mineralization, and the
appearance of multinucleated giant cells characteristic of
osteoclasts seemed to be associated with absorption of
b-TCP, and new bone formation was associated with
angiogenesis in group A. In group B, fibroblast-like cells
expanded, and angiogenesis and immature bone forma-
tion was seen to a lesser extent than in group A.
Absorption of b-TCP was unclear. Thus, histological
changes toward healing of the bone defect in group A
Fig. 4 Macroscopic appearance of the defects 8 weeks postopera-
tively. Group A were treated with a mixture of b-tricalcium phosphate
(b-TCP), collagen, and hepatocyte growth factor (HGF); group B
were treated with b-TCP and collagen. These photographs are
representative of each experimental group
Fig. 5 Coronal view of the central defects by micro-computed
tomography (CT) at 4 and 8 weeks postoperatively. Group A were
treated with a mixture of b-tricalcium phosphate (b-TCP), collagen,
and hepatocyte growth factor (HGF); group B were treated with
b-TCP and collagen. Six rabbits in each group were examined by use
of micro-CT and representative photographs in each group are shown
Fig. 6 Change in biomechanical strength of segmental bone defect
sites at 4 and 8 weeks postoperatively. Group A were treated with a
mixture of b-tricalcium phosphate (b-TCP), collagen, and hepatocyte
growth factor (HGF) (n = 20); group B were treated with b-TCP and
collagen (n = 20). Because union of the bone defect was impaired at
8 weeks in the untreated control group, they were excluded from this
analysis
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took less time than in group B (Fig. 7a). Six weeks post-
operatively, multiple islands of newly formed bone were
integrated, and woven bone structures clearly appeared in
group A. Absorption of b-TCP had progressed further than
at 4 weeks. In group B, new bone formation appeared, and
this was associated with angiogenesis and absorption of
b-TCP (Fig. 7b).
After 8 weeks, newly generated bone was replaced
by bone marrow tissue, and the b-TCP granules were
mostly absorbed and had disappeared in group A. In
group B, new bone formation had progressed further
after 6 weeks, and woven bone structures had appeared.
Thus, although histological changes similar to those in
group A occurred in group B, the amount and rate of
new bone formation was less and slower than that of
group A. Absorption of b-TCP granules occurred but
some granules still remained at the end of 8 weeks in
group B (Fig. 7b).
Fig. 7 Histological changes
during healing of the segmental
bone defects. Tissue sections
were stained with H&E. Group
A were treated with a mixture of
b-tricalcium phosphate
(b-TCP), collagen, and
hepatocyte growth factor (HGF)
(n = 20); group B were treated
with b-TCP and collagen
(n = 20). Representative
longitudinal histological
sections of both groups 2, 4, 6,
and 8 weeks after surgery are
shown
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Measurement of newly formed bone
and residual b-TCP area
The area rates of new bone formation in groups A and B
were, respectively, 2.5 and 0.4 % at 2 weeks, 19.2 and
10.4 % at 4 weeks, and 28.8 and 25.9 % at 6 weeks. The
area rate of new bone formation in group A was larger than
that of group B at 2, 4, and 6 weeks. However, at 8 weeks,
the area rate of new bone formation in group A was smaller
than that of group B (36.0 vs. 42.3 %). No statistical dif-
ference was observed between the groups at any time
(Fig. 8a). The area rates of residual b-TCP in groups A and
B were, respectively, 41.3 and 51.1 % at 2 weeks, 18.1 and
31.6 % at 4 weeks, 14.1 and 19.6 % at 6 weeks, and 6.1
and 11.4 % at 8 weeks. The area rate of residual b-TCP in
group A was smaller than that of group B at any time
period. Although the area rate of residual b-TCP in group
A was significantly smaller than that of group B at
4 weeks, no statistical difference was observed between the
groups at other time periods (Fig. 8b).
Discussion
Extracellular scaffold proteins, bioactive substances, and
osteogenic progenitor cells induce bone formation or pro-
mote osteogenesis by enhancing osteogenic cell migration,
proliferation, and differentiation [3]. In tissue engineering,
incorporation of one or more of the fundamental elements
needed to regenerate bone tissue, for example scaffold
proteins, bioactive substances, or osteogenic progenitor
cells into the target site is the basic strategy used to
promote bone regeneration in situ. In this study, we
demonstrated that the complex of human recombinant
HGF, b-TCP, and collagen promoted bone healing in a
rabbit model of segmental bone defects and increased the
mechanical strength of the bone defect in rabbit, particu-
larly at an early stage.
Previous studies have demonstrated therapeutic actions
of HGF in different disease models in different tissues,
including the liver, kidney, lung, and nervous tissue [9, 18].
Consistently, tissue-selective disruption of the Met gene in
the liver, kidney, or epidermis indicated impairment in
regeneration and healing and/or an increase in epithelial
apoptosis [26, 27]. Compared with understanding of the
physiological functions of HGF in tissues originating from
endodermal and epithelial cells, for example the liver and
nervous tissue, the physiological function and biological
activity of HGF during bone metabolism and regeneration
have yet to be addressed, perhaps because early studies
indicated that the Met receptor is expressed in a variety of
epithelial cells. However, studies conducted in the past
several years have revealed biological activity of the HGF-
Met pathway during bone metabolism and fracture healing.
HGF and its receptor, c-Met, are expressed in both osteo-
blasts and osteoclasts [19]. HGF, in combination with
vitamin D3, promotes growth and differentiation of
human mesenchymal cells into osteogenic cells [20]. HGF
enhances differentiation of osteoblasts [21] and induces the
expression of BMP receptors during the early phase of
fracture repair [13].
Biocompatibility, osteoconductivity, an interconnected
porous structure enabling neovascularization, mechanical
strength, and biodegradability are appropriate characteris-
tics of scaffold materials for bone regeneration [22]. b-TCP
and hydroxyapatite are osteoconductive and biocompatible
with bone tissue, whereas b-TCP, but not hydroxyapa-
tite, is biodegradable. A paste-like composite of b-TCP
granules and collagen, which we used in this study, is
applicable to defects of any shape and is easy to handle.
In geriatric osteoporotic rats, PDGF-BB in a mixture of
Fig. 8 Changes in areas of new bone formation (a) and the remaining
b-tricalcium phosphate (b-TCP) (b). Group A were treated with a
mixture of b-TCP, collagen, and hepatocyte growth factor (HGF)
(n = 20); group B were treated with b-TCP and collagen (n = 20).
The areas of new bone formation and b-TCP were quantified using
color-based thresholding and image-analysis software (WinRoof) and
expressed as a percentage of the area analyzed. A representative
photograph for determination of these areas is shown in Fig. 2
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b-TCP and collagen promotes healing of bone fractures
after a tibial osteotomy, compared with the material with-
out PDGF-BB [6]. In rabbits, FGF-2 in a mixture of b-TCP
and collagen facilitates healing of segmental bone defects
[17]. BMP-2 in gelatin-based sponges containing b-TCP
has higher osteoinductive activity at bone-defect sites than
sponges that do not contain BMP-2 [16]. The results pre-
sented in this paper indicate that HGF in a complex of
b-TCP and collagen added to tibial osteotomy gaps effec-
tively promoted bone repair and b-TCP absorption. Taken
together, these polypeptide growth factors potentiate the
effectiveness of b-TCP for healing bone defects in less
time and with better biomechanical quality than b-TCP
alone, whereas b-TCP provides a delivery system for
polypeptide growth factors, thereby promoting the osteo-
inductive environment.
HGF has strong angiogenic properties [10, 23], and
neovascularization is fundamental for bone development
and regeneration, supplying blood cells, oxygen, minerals,
ions, glucose, hormones, and growth factors [25]. For
osteoblasts and osteoclasts, HGF stimulates proliferation of
osteoblasts and chemotactic migration and replication of
osteoclasts [24]. In this study, we showed that along with
the activation of new bone formation, more extensive blood
vessels were formed in bone defects to which HGF was
applied than those without HGF. b-TCP absorption was
much accelerated in the defective regions in the HGF-
treated group compared to the group without HGF. Eight
weeks after surgery, most of the b-TCP was absorbed and
replaced by newly formed bone in the HGF-treated group,
whereas b-TCP granules remained in defected regions
without HGF. Previous studies indicated that osteoclasts
are of major importance in bioresorption of b-TCP [28].
Inhibition of osteoblast formation resulted in reduced
b-TCP resorption and bone formation, suggesting a cou-
pling between osteoclast-mediated b-TCP resorption and
bone formation [29]. Taken together, we assume that HGF-
induced angiogenesis, mesenchymal cell proliferation, and
osteoclasts’ migration and proliferation were responsible
for promoting bone formation, the appearance of osteo-
clasts around the b-TCP, and facilitated b-TCP resorption.
The histological analysis revealed that HGF promoted
new bone formation in defective regions and this was
associated with recovery of biomechanical strength during
the early stages of bone regeneration within 4 weeks. No
significant differences in biomechanical recovery were
observed between the groups with or without HGF 8 weeks
postoperatively. The biological activity of HGF such as
angiogenesis and promotion of growth of mesenchymal
progenitor cells and their differentiation into osteoblasts is
more important in the early stages of bone regeneration
than in the late stages. HGF contributes to fracture repair
by inducing BMP receptor expression during the early
stage of the repair [13]. Although significant reduction in
biological activity of HGF in solution at 37 C is not seen
at least for 1 week (unpublished data), at the injury site
HGF might be potentially inactivated because of several
proteases, for example elastase, which is secreted by
inflammatory cells. Thus, HGF has biological activity that
is important in the early stage of bone healing, rather than
the late stages, thereby leading to rapid histological and
biomechanical healing within 4 weeks. Additionally, it
seemed likely that release and delivery of HGF from the
complex of b-TCP and collagen may occur earlier than the
biological degradation of b-TCP, thereby enabling HGF to
exert its biological actions during the early stages of bone
regeneration.
Our results suggest the potential application of HGF for
treating bone defects or bone fractures; however, several
issues should be addressed before clinical application.
HGF has substantial affinity for different types of collagen
and collagen-bound HGF is biologically active [30]. Thus,
the mixture of type-1 collagen and b-TCP was expected to
provide a biodegradable scaffold for local delivery of
HGF. On the other hand, previous studies using local
administration of HGF in various models in different
species including rabbit revealed significant therapeutic
effects of 100 lg HGF [11, 31–34]. Therefore, we selected
a dose of 100 lg HGF/injection for the HGF/b-TCP/col-
lagen complex because HGF was expected to exert bio-
logical effects and we could evaluate if HGF would have
therapeutic benefits in this rabbit model. However, the
chemical stability and pharmacological availability of
HGF released from the HGF/b-TCP/collagen complex, and
the optimum dose of HGF, should be determined in sub-
sequent preclinical studies before future clinical studies.
Likewise, the potential risk of stimulation of premalignant
lesions by HGF should be tested. Nevertheless, we have
obtained evidence, for the first time, that recombinant
human HGF combined with b-TCP and collagen promoted
bone healing and increased biomechanical strength of a
bone defect in rabbits, particularly at an early stage. HGF
and b-TCP could shorten the period for bone healing and
fusion and could be implanted during a single surgery,
perhaps without preparation of bone for an autograft,
thereby reducing surgical time. Overall, these changes are
expected to improve the physical and mental well-being of
patients.
Conclusion
In a rabbit osteotomy model, HGF combined with b-TCP
and collagen in a matrix promoted bone healing and
increased mechanical strength, particularly at the early
stage of healing.
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